GAITHERSBURG, Md., Oct. 19 /PRNewswire-FirstCall/ -- Iomai Corporation announced that Chief Scientific Officer Gregory Glenn, M.D., will today detail the company’s influenza vaccine program during a session titled: “Vaccination Routes,” as part of the “Influenza Vaccines for the World” conference at the Palais Ferstl in Vienna, Austria. Dr. Glenn will also moderate the session.
The session will begin at 3:20 p.m. with Dr. Glenn’s presentation, “Transcutaneous Influenza Vaccine.”
The presentation will describe Iomai’s influenza program development. The company has two Phase 1 programs: a needle-free vaccine patch intended to replace traditional intramuscular injection and an adjuvant-based patch designed to boost the response to traditional vaccination in the elderly. In addition, Dr. Glenn will discuss the company’s development of a patch that can be used in combination with pandemic influenza vaccines to boost response and allow for lower vaccine doses to be used.
Dr. Glenn, the founder of Iomai, developed the company’s proprietary TCI (transcutaneous immunization) technology. This needle-free technology uses a patch placed on the surface of the skin to deliver vaccines and adjuvants via a group of antigen-presenting cells in the skin (Langerhans cells) to the nearby lymph nodes to produce a sustained immune response. Multiple benefits of the patch technology include needle-free administration and the ability to deliver vaccines that could not effectively be delivered using a traditional intramuscular (IM) injection.
ABOUT IOMAI CORPORATION
Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent E. coli-related travelers’ diarrhea. For more information on Iomai, please visit www.iomai.com.
Some matters discussed in this press release constitute “forward-looking statements” that involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. Such forward-looking statements include statements about Iomai’s ability to stimulate stronger immune responses, the ability of Iomai’s patches to expand the supply of pandemic flu vaccine and otherwise expand vaccine markets, and the benefits of its patch technology. Applicable risks and uncertainties include, among others, that results in future Phase 2 and Phase 3 trials may not replicate results seen in the trials described in this press release; that Iomai may not be able to enroll sufficient numbers of patients in future clinical trials; that Iomai may be unable to obtain the regulatory approvals necessary to conduct additional clinical trials or to market any product candidates for travelers’ diarrhea or pandemic flu; that development costs may exceed expectations; that Iomai may fail to adequately protect its intellectual property or may be determined to infringe on the intellectual property of others; and the risks identified under the heading “Risk Factors": in the Company’s Quarterly Report on Form 10-Q for the three months ended June 30, 2006 and its Annual Report on Form 10-K for the year ended December 31, 2005 and filed with the Securities and Exchange Commission. Iomai cautions investors and others not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read the Company’s filings for a discussion of these and other risks and uncertainties which are filed with the U.S. Securities and Exchange Commission, available at www.sec.gov.
These statements speak only as of the date of this document, and Iomai undertakes no obligation to update or revise the statements.
Iomai Corporation
CONTACT: Russell P. Wilson, Senior Vice President, Chief Financial Officerand General Counsel of Iomai Corporation, +1-301-556-4478, orinvestors@iomai.com; or Brian Reid of WeissComm Partners, Inc.,+1-703-402-3626, or breid@weisscommpartners.com
Web site: http://www.iomai.com/
